ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.
Roxsan ManshouriEtienne CoyaudSamrat T KunduDavid H PengSabrina A StrattonKendra L AlltonRakhee BajajJared J FradetteRosalba MinelliMichael D PeoplesAlessandro CarugoFengju ChenChristopher BristowJeffrey J KovacsMichelle Craig BartonTim HeffernanChad J CreightonBrian RaughtDon L GibbonsPublished in: Nature communications (2019)
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, due in part to the propensity of lung cancer to metastasize. Aberrant epithelial-to-mesenchymal transition (EMT) is a proposed model for the initiation of metastasis. During EMT cell-cell adhesion is reduced allowing cells to dissociate and invade. Of the EMT-associated transcription factors, ZEB1 uniquely promotes NSCLC disease progression. Here we apply two independent screens, BioID and an Epigenome shRNA dropout screen, to define ZEB1 interactors that are critical to metastatic NSCLC. We identify the NuRD complex as a ZEB1 co-repressor and the Rab22 GTPase-activating protein TBC1D2b as a ZEB1/NuRD complex target. We find that TBC1D2b suppresses E-cadherin internalization, thus hindering cancer cell invasion and metastasis.
Keyphrases
- epithelial mesenchymal transition
- signaling pathway
- small cell lung cancer
- induced apoptosis
- cell adhesion
- advanced non small cell lung cancer
- long non coding rna
- high throughput
- pi k akt
- transcription factor
- squamous cell carcinoma
- single cell
- dna methylation
- brain metastases
- cell cycle arrest
- stem cells
- genome wide
- cell therapy
- gene expression
- small molecule
- endoplasmic reticulum stress
- bone marrow